Navigation Links
Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study
Date:2/26/2009

y 11%, P=0.035). This was mainly driven by 24% reduction in nonfatal MI (P=0.01) and 21% reduction in coronary revascularisation (P=0.003).(5)

There was also evidence of benefit with fenofibrate for microvascular endpoints, in particular reduction in first laser treatment for retinopathy (by 31%, P=0.0002).(6, 7)

What is the metabolic syndrome?

The metabolic syndrome is characterised by a clustering of cardiovascular risk factors which increase the risk of type 2 diabetes and cardiovascular disease. Although the definition of metabolic syndrome varies among different guidelines, one of the most widely accepted is that of the NCEP ATPIII(4) which defines metabolic syndrome by the following criteria:

    -- Abdominal obesity (waist circumference >40 inches in men and
       >35 inches in women) AND
    -- Triglycerides greater than or equal to 150 mg/dL
    -- HDL cholesterol <40 mg/dL in men and <50 mg/dL in women
    -- Blood pressure greater than or equal to 130/85 mmHg (or on
       antihypertensive treatment)
    -- Elevated fasting plasma glucose (greater than or equal to 100 mg/dL).

What is meant by number needed to treat?

The NNT value provides a clinical context to the absolute reduction in risk. This value is defined by the inverse of the absolute reduction in risk. In this analysis, the NNT for fenofibrate in patients with marked atherogenic dyslipidaemia was 23 patients needing to be treated for one event to be prevented.

By comparison, the Cholesterol Treatment Trialists' (CTT) Collaborators (8) reported an absolute reduction in 5-year risk of major vascular events in diabetes patients treated with statin therapy of 3.6%, i.e. NNT = 28.

References

1. Russell Scott, Richard O'Brien, Greg Fulcher, Chris Pardy, Michael d'Emden, Dana Tse, Maria-Riitta Taskinen, Christian Ehnholm, Anthony Keech
'/>"/>

SOURCE Solvay
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. February 2009 Mayo Clinic Womens HealthSource Highlights Diabetes and Heart Disease, Going Vegetarian and Tinnitus
2. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
3. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
4. Epidemics of Both Type 1 Diabetes (Insulin Dependent) and Type 2 Diabetes (Obesity Related) Are Linked to Immunization
5. Overweight Siblings of Children With Type 2 Diabetes Likely to Have Abnormal Blood Sugar Levels
6. Patient Recruitment Begins in India for Phase 3 Diabetes Trial
7. Opportunities to Highlight Type 1 Diabetes in November
8. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
9. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
10. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program
11. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Reportlinker.com announces that a new market ... Portugal Pharmaceuticals and Healthcare Report Q3 ... Includes 3 FREE quarterly updates ... last quarter has led us to revise our ... previously, BMI expects Portugal,s ...
(Date:7/28/2014)... CLEVELAND , July 28, 2014  Surgical ... new members to its Business Advisory Board. New ... Senior Vice President for Business Development and New ... (Jim) Fulton , former Senior Vice President and ... unit. Surgical Theater applies flight simulation technology to ...
(Date:7/28/2014)... , July 28, 2014  Serco Inc., a ... the Company has been awarded a re-compete contract ... (NEMSCOM) and its Deployable Medical Systems.  Serco will ... personnel to provide world-class healthcare to meet warfighter ... across the globe. The five year contract has ...
Breaking Medicine Technology:Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 2Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 3Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 4Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 5Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... , ATLANTA, Dec. 23 MiMedx Group, Inc. ... launched its first product, Paradis Vaso Shield(TM). In April ... for use as a cover for vessels following anterior vertebral ... hydrogel product protected by multiple patents and patent applications, as ...
... FRANCISCO, Dec. 23 Jennerex Biotherapeutics, a clinical-stage biotherapeutics company developing ... that management will present at the following upcoming investor conferences. , ... January 12, 2010, 9:40 a.m. PT, ... OneMedForum 2010, Wednesday, January 13, 2010, ...
Cached Medicine Technology:MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device 2MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device 3
(Date:7/28/2014)... The American Society of ... engaged in the field of organ transplantation, today ... Immunology Research Network (TIRN), a professional network ... modern organ transplantation continues to diversify, AST determined ... more opportunities for physicians, scientists and researchers to ...
(Date:7/28/2014)... Research into improving treatment for patients with one of ... 810,000 funding boost. , Chronic obstructive pulmonary disease (COPD) ... cause breathing difficulties due to long-term damage to the ... for 10 per cent of all hospital admissions in ... readmitted to hospital after they are discharged. ...
(Date:7/28/2014)... Malibu, CA (PRWEB) July 28, 2014 ... upon us, it is welcome news that a ... effective than current protection is under development by SunSeeker ... by NASA to protect spacecraft from the extreme heat ... protection to both firefighters and homes. , “Our firefighters ...
(Date:7/28/2014)... 28, 2014 Drorit Silverman, a professional ... plans to raise investment capital through her crowd funding ... in the United States. , According to a statement ... fitness centers provide a great window of opportunity for ... space. In addition to this, Silverman looks at the ...
(Date:7/28/2014)... (Boston)-- Researchers from Boston University School of Medicine (BUSM) ... increase the risk of developing Alzheimer,s disease (AD). The ... new drug treatment options that target PLXNA4 specifically. These ... , AD is the most frequent age-related dementia affecting ... 65 and older, and more than 40 percent of ...
Breaking Medicine News(10 mins):Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:Researchers identify potential biomarker for AD 2
... and Treatment Centers Seek Competitive Advantage by Leveraging ... to make ends meet, the ability to do ... gain efficiencies comes from two converging market forces: ... recession-proof healthcare industry, and the national push to ...
... will be made available closer to the meeting date. ... the meeting as well as during the meeting. , ... Council of the National Academy of Sciences. The Society,s ... and to encourage applications of research findings. Its membership ...
... QC, April 2 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: ... the results of its recently completed North American ... of tramadol and acetaminophen (study 06CCL3-001). , Study ... that compared the efficacy and safety of Labopharm,s ...
... connect, exchange information and ,speak, HL7. , ... Toronto, ... - a core need in modern healthcare - has never been ... HL7 Interface Engine . This easy-to-use yet powerful tool, ...
... through common symptoms during pregnancy, such as morning sickness, fatigue and weight ... when they come. At Gurgle, we offer a guide to women in ... , ... London, England (PRWEB) April 2, 2009 -- Around half of ...
... NY -- Biomedical informatics researchers at Mayo Clinic ... the newly founded Open Health Natural Language Processing ... space to promote past and current development efforts, ... records. , As part of the launch, Mayo ...
Cached Medicine News:Health News:Hospitals Turn to Vendors Like Elekta for Help in Squeezing Most From Existing Technologies 2Health News:Hospitals Turn to Vendors Like Elekta for Help in Squeezing Most From Existing Technologies 3Health News:Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation 2Health News:Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation 3Health News:Talking Iguana - Helping the Healthcare Sector Speak HL7 2Health News:Talking Iguana - Helping the Healthcare Sector Speak HL7 3Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 2Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 3Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 4Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 5Health News:Mayo Clinic and IBM host medical language initiative 2Health News:Mayo Clinic and IBM host medical language initiative 3Health News:Mayo Clinic and IBM host medical language initiative 4
...
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
... a patented HEp-2 cell line that has ... to SS-A/Ro autoantibodies, without affecting the other ... been published worldwide on the HEp-2000 ANA ... autoantibodies when used in place of standard ...
Medicine Products: